The frequency of p53 mutations in primary tumors, the effect of the mutations on some clinical and pathological features of head and neck squamous cell carcinoma, and the impact of p53 mutations in the surgical margins on local recurrence were determined.
Material and Methods
We investigated the presence of p53 mutations in primary tumor samples and in the surgical margins of 34 patients with head and neck cancer using single strand conformational polymorphism and sequencing analysis.
Results
The p53 mutations (codons 175addAT, 175delGC, 206G→A, and 248delC) were found in the primary tumor samples of 15 of 34 patients (44.12%) and in the surgical margins of 5 of the 15 tumors (33.33%) with p53 mutations.
Conclusions
We found no statistically significant association between the presence of p53 mutations in the primary tumor, the clinical and pathological features, or outcome of head and neck squamous cell carcinoma in this study. Furthermore, the presence of p53 mutations in the surgical margins may not increase the risk of local-regional recurrence, but probably increases the risk of developing distant metastases or second primary tumors.
BoringC.C., SquireT.S., TongT.: Cancer statistics.CA Cancer J Clin, 42: 18–381, 1992.
2.
TuynsA.J., EsteveJ., RaymondL., BerrinoF., BenhamouE., BlanchetF., BoffettaP., CrosignaniP., del MoralA., LehmannW., MerlettiF., PequignotG., RreouE., Sancho-GarnierH., TerraciniB., ZubiriA., ZubiriL.: Cancer of larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France).Int J Cancer, 41: 483–491, 1988.
3.
EgeliU., OzkanL., TuncaB., KahramanS., CecenerG., ErgulE., EnginK.: The relationship between genetic susceptibility to head and neck cancer with the expression of common fragile sites.Head Neck, 22: 591–598, 2000.
4.
CalifanoJ., Van der RietP., WestraW., NawrozH., ClaymanG., PiantodosiS., CorioR., LeeD., GreenbergB., KochW., SidranskyD.: Genetic progression model for head and neck cancer: implications for field cancerization.Cancer Res, 56: 2488–2492, 1996.
5.
BlonsH., Laurent-PuigP.: TP53 and head and neck neoplasms.Hum Mutat, 21: 252–257, 2003.
6.
SaundersM.E., MacKenzieR., ShipmanR., FransenE., GilbertR., JordanR.C.: Patterns of p53 gene mutations in head and neck cancer: Full-length gene sequencing and results of primary radiotherapy.Clin Cancer Res, 5: 2455–2463, 1999.
7.
AlsnerJ., SorensenS.B., OvergaardJ.: TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.Radiother Oncol, 59: 179–185, 2001.
8.
BrennanJ.A., BoyleJ.O., KochW.M., GoodmanS.N., HrubanR.H., EbyY.J., CouchM.J., ForastiereA.A., SidranskyD.: Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck.N Engl J Med, 332: 712–717, 1995.
9.
CabelguenneA., BlonsH., de WaziersI., CarnotF., HoullierA.M., SoussiT., BrasnuD., BeauneP., LaccourreyeO., Laurent-PuigP.: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.J Clin Oncol, 18: 1465–1473, 2000.
10.
GillisonM.L., KochW.M., CaponeR.B., SpaffordM., WestraW.H., WuL., ZahurakM.L., DanielR.W., ViglioneM., SymerD.E., ShahK.V., SidranskyD.: Evidence for a casual association between human papillomavirus and a subset of head and neck cancers.J Natl Cancer Inst, 92: 709–720, 2000.
11.
KoY., AbelJ., HarthV., BrodeP., AntonyC., DonatS., FischerH.P., Ortiz-PallardoM.E., ThierR., SachinidisA., VetterH., BoltH.M., HerberholdC., BruningT.: Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue.Cancer Res, 61: 4398–4404, 2001.
12.
TemamS., FlahaultA., PerieS., MonceauxG., CouletF., CallardP., BernaudinJ.F., St GuilyJ.L., FouretP.: p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.J Clin Oncol, 18: 385–394, 2000.
13.
BoyleJ.O., HakimJ., KochW., van der RietP., HrubanR.H., RoaR.A., CorreoR., EbyY.J., RuppertJ.M., SidranskyD.: The incidence of p53 mutations increases with progression of head and neck cancer.Cancer Res, 53: 4477–4480, 1993.
14.
HoutenV.M.M., TaborM.P., BrekelM.W.M., KummerA., DenkersF., DijkstraJ., LeemansR., WallI., SnowG.B., BrakenhoffR.H.: Mutated p53 as a molecular marker for the diagnosis of the head and neck cancer.Pathology, 198: 476–486, 2002.
15.
LeemansC.R., TiwariR., NautaJ.J., Van der WaalI., SnowG.B.: Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor.Cancer, 73: 187–190, 1994.
16.
HermanekP., HutterR.V., SobinL.H., WittekindC.: Classification of isolated tumor cells and micrometastasis.Cancer, 86: 2668–2673, 1999.
17.
HongyoT., BuzardG.S., PalliD., WeghorstC.M., AmorosiA., GalliM., CaporasoN.E., FraumeniJ.F.Jr., RiceJ.M.: Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy.Cancer Res, 55: 2665–2672, 1995.
18.
SangerF., NicklenS., CaulsonA.R.: DNA sequencing with chain-terminating inhibitors.Proc Natl Acad Sci USA, 74: 463–67, 1977.
19.
ToyookaS., TsudaT., GazdarA.F.: The TP53 gene, tobacco exposure and lung cancer.Hum Mutat, 21: 229–239, 2003.
20.
VosM., AdamsC.H., VictorT.C., van HeldenP.D.: Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa.Cancer Genet Cytogenet, 140: 23–30, 2003.
21.
MontesanoR., HollsteinM., HainautP.: Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review.Int J Cancer (Pred Oncol), 69: 225–235, 1996.
22.
WagaraT., ShibagakiI., ImamuraM., ShimadaY., ToguchidaJ., YandellD.W., IkenagaM., TobeT., IshizakiK.: Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas.Cancer Res, 53: 846–850, 1993.
23.
BeroudC., SoussiT.: The UMD-p53 Database: New mutations and analysis tools.Hum Mutat, 21: 176–181, 2003.
24.
SoussiT., DehoucheK., BeroudC.: P53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis.Hum Mutat, 15: 105–113, 2000.
25.
IacopettaB.: TP53 mutation in colorectal cancer.Hum Mutat, 21: 271–276, 2003.
26.
HainautP., OliverM., PfeiferG.P.: TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database.Mutagenesis, 16: 551–553, 2001.
27.
SmithL.E., DenissenkoM.F., BennettW.P., LiH., AminS., TangM., PfeiferG.P.: Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons.J Natl Cancer Inst, 92: 803–811, 2000.
28.
BerghJ., NorberkT., SjogrenS., LindgrenA., HolmbergL.: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.Nat Med, 1: 1029–1034, 1995.
29.
PowellB., SoongR., IacopettaB., SeshadriR., SmithD.R.: Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.Clinical Cancer Res, 6: 443–451, 2000.
30.
JinY.T., KayserS., KempB.L., OrdonezN.G., TuckerS.L., ClaymanG.L., GoepfertH., LunaM.A., BatsakisJ.G., El-NaggarA.K.: The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma.Cancer, 82: 2159–2165, 1998.
31.
ShinD.M., MaoL., PapadimitrakopoulouV.M., ClaymanG., El-NaggarA., ShinH.J., LeeJ.J., LeeJ.S., GillenwaterA., MyersJ., LippmanS.M., HittelmanW.N., HongW.K.: Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression.J Natl Cancer Inst, 92: 69–73, 2000.
32.
GeorgiouA., GomatosI.P., FerekidisE., SyrigosK., BistolaV., GiotakisJ., AdamopoulosG., AndroulakisG.: Prognostic significance of p53, bax and bcl-2 gene expression in patients with laryngeal carcinoma.Eur J Surg Oncol, 27: 574–580, 2001.
HirvikoskiP., KumpulainenE., VirtaniemiJ., JohanssonR., HaapasaloH., MarinS., HalonenP., HelinH., RaitiolaH., PukanderJ., Kellokumpu-LehtinenP., KosmaV.M.: P53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma.J Clin Oncol, 15: 3111–3120, 1997.
35.
JeannonJ.P., SoamesJ., LunecJ., AwwadS., AshtonV., WilsonJ.A.: Expression of cylin-dependent kinase inhibitor p21 (WAF1) and p53 tumour suppressor gene in laryngeal cancer.Clin Otolaryngol, 25: 23–27, 2000.
36.
KokoskaM.S., PiccirilloJ.F., el-MoftyS.K., EmamiB., HaugheyB.H., SchoinickS.B.: Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy.Cancer, 78: 1693–1700, 1996.
37.
SittelC., EckelH.E., DammM., von PritzbuerE., KvasnickaH.M.: Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.Laryngoscope, 110: 1012–1017, 2000.
38.
MinetaH., BorgA., DictorM., WahlbergP., AkervallJ., WennerbergJ.: p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.Br J Cancer, 78: 1084–1090, 1998.
39.
BandohN., HayashiT., KishibeK., TakaharaM., ImadaM., NonakaS., HarabuchiY.: Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma.Cancer, 94: 1968–1980, 2002.
40.
BradfordC.R., ZhuS., PooreJ., FisherS.G., BealsT.F., ThoravalD., HanashS.M., CareyT.E., WolfG.T.: P53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of veterans affair laryngeal cancer cooperative study group.Arch Otolaryngol Head Neck Surg, 123: 605–609, 1997.
41.
ChowV., YuenA.P., LamK.Y., HoW.K., WeiW.I.: Prognostic significance of serum p53 protein and p53 antibady in patients with surgical treatment for head and neck squamous cell carcinoma.Head Neck, 23: 286–291, 2001.
42.
GalloO., ChiarelliI., BoddiV., BoccioliniC., BruschiniL., PorfirioB.: Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy.Int J Cancer, 84: 573–579, 1999.
43.
PartridgeM., LiS.R., PateromichelakisS., FrancisR., PhillipsE., HuangX.H., Tesfa-SelaseF., LangdonJ.D.: Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment.Clinical Cancer Res, 6: 2718–2725, 2000.
44.
BrennanJ.A., MaoL., HrubanR.H., BoyleJ.O., EbyY.J., KochW.M., GoodmanS.N., SidranskyD.: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck.N Engl J Med, 332: 429–435, 1995.
45.
TaborM.P., BrakenhoffR.H., van HoutenV.M.M., KummerA., SnelM.H.J., SnijdersP.J.F., SnowG.B., LeemansC.R., BraakhuisB.J.M.: Persistence of genetically altered fields in head and neck cancer patients: Biological and clinical implications.Clinical Cancer Res, 7: 1523–1532, 2001.
46.
MaoL., LeeJ.S., FanY.H., RaoJ.Y., BatsakisJ.G., LippmanS., Hi-HelmanW., HongW.K.: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment.Nature Med, 2: 682–685, 1996.
47.
RosinM.P., ChengX., PohC., LamW.L., HuangY., LovasJ., BereanK., EpsteinJ.B., PriddyR., LeN.D., ZhangL.: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.Clin Cancer Res, 6: 357–362, 2000.
48.
PatridgeM., PateromichelakisS., PhillipsE., EmilionG.G., A'HernR.P., LangdonJ.D.: A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma with in a field of cancerization.Cancer Res, 60: 3893–3898, 2000.
